#None #Synaffix #Lonza #Sidewinder

Strategic Alliance Between Lonza's Synaffix and Sidewinder Therapeutics

In a noteworthy development within the biopharmaceutical sector, Lonza's Synaffix B.V. has formed a multi-target licensing agreement with Sidewinder Therapeutics. This partnership is set to pave the way for the creation of next-generation bispecific antibody-drug conjugates (ADCs). By integrating Sidewinder's innovative bispecific ADC pipeline with Lonza's clinically validated technology platform, this collaboration aims to enhance tumor-cell internalization, particularly for the treatment of various solid tumor indications.

Significance of the Collaboration

The licensing agreement offers Sidewinder access to a range of cutting-edge technologies from Lonza. Included in this arsenal are the GlycoConnect® antibody conjugation technology, the HydraSpace® polar spacer technology, and the innovative toxSYN® linker payload. This comprehensive suite of technologies positions Sidewinder to develop first-in-class therapeutics that promise to maximize targeting accuracy while minimizing harm to healthy tissues.

Under the terms of the agreement, Lonza anticipates receiving a series of payments based on clinical and regulatory milestones, as well as a share of royalties from the sales of the resulting products. While Lonza will manufacture components related to its proprietary technologies, Sidewinder is charged with the research, development, manufacturing, and commercialization of the ADCs.

Insights from Company Leaders

Peter van de Sande, who heads Synaffix at Lonza, expressed enthusiasm regarding the strategic alliance. He remarked, "This collaboration merges two pioneering platforms, enhancing how bispecific ADCs perform while minimizing impact on healthy tissue. We believe our technologies will empower Sidewinder’s pipeline to reach its full potential in maximizing tumor targeting, ultimately leading to lifesaving therapies for cancer patients."

On the other side, Eric Murphy, Co-Founder and CEO of Sidewinder Therapeutics, highlighted the timely nature of advancements within the ADC landscape, stating, "The ADC field has woken up, driven by technological breakthroughs that usher in a new era of bispecific ADC innovation. By combining Sidewinder's bispecific antibody strategy with Synaffix's validated technologies, we are poised to make a meaningful difference in cancer treatment."

About the Companies Involved

Lonza

Recognized as one of the world's foremost development and manufacturing organizations, Lonza operates on a global scale across five continents. The company employs over 19,000 professionals dedicated to partnering with pharmaceutical and biotech firms to translate innovative ideas into effective therapies. With reported sales of CHF 3.6 billion and a CORE EBITDA of CHF 1.1 billion in the first half of 2025, Lonza is committed to bringing transformative treatments to patients worldwide through advanced science and streamlined manufacturing processes.

Synaffix

Synaffix is a biotechnology pioneer specializing in ADC technologies. The company's unique platform capitalizes on GlycoConnect®, HydraSpace®, and toxSYN® innovations to enable various organizations to create proprietary ADC products under a single licensing agreement. With established patents and a focus on target-specific technology out-licensing, Synaffix facilitates faster clinical timelines through a robust supply chain. Its complete acquisition by Lonza in June 2023 further solidifies its market position.

Sidewinder Therapeutics

Founded in 2023, Sidewinder Therapeutics centers its efforts on developing cutting-edge, large-molecule precision therapeutics, particularly in the realm of bispecific ADCs. By targeting specific tumor complexes to improve specificity and internalization, the company seeks to broaden the therapeutic window for cancer treatments. With plans to initiate a clinical trial for its flagship bispecific ADC in 2026, Sidewinder is well-positioned for impactful advancements in oncology. Supported by a Series A investment from OrbiMed, the company's headquarters are based in San Diego, CA.

Conclusion

The partnership between Lonza's Synaffix and Sidewinder Therapeutics stands as a promising development in the biotechnology field. Through strategic collaboration, both entities aim to push the boundaries of cancer treatment by leveraging innovative technologies to create efficient and effective therapeutic solutions against solid tumors. As advancements in bispecific ADCs unfold, the biomedical landscape may witness significant improvements in patient care and outcomes.